Related Experiment Video
Updated: Apr 7, 2026

Characterization of Functionally Associated miRNAs in Glioblastoma and their Engineering into Artificial Clusters for Gene Therapy
Published on: October 4, 2019
Compound 331 selectively induces glioma cell death by upregulating miR-494 and downregulating CDC20
Lei Zhang1, Tianhui Niu2, Yafei Huang3
1State Key Laboratory of Biomembrane and Membrane Biotechnology, College of Life Sciences, PKU-IDG/McGovern Institute for Brain Research, Peking University, Beijing, 100871, China.
Abstract:
Malignant gliomas are the most common malignant tumors in the central nervous system (CNS). Up to date, the prognosis of glioma is still very poor, effective therapy with less side-effect is very necessary. Herein, we identify a compound named as "331" selectively induced cell death in glioma cells but not in astrocytes. Compound 331 upregulated miR-494 and downregulated CDC20 in glioma cells but not in astrocytes. These results suggest that compound 331 could be a potential drug selectively targeting glioma cells through upregulating miR-494 and downregulating CDC20.
Insights
A novel compound, "331," selectively induces cell death in malignant glioma cells, not normal astrocytes. This targeted therapy upregulates miR-494 and downregulates CDC20, offering a promising new treatment for brain tumors.
Area of Science:
- Neuro-oncology
- Molecular Biology
- Drug Discovery
Background:
- Malignant gliomas represent the most frequent primary central nervous system (CNS) tumors.
- Current glioma prognoses remain poor, necessitating novel therapeutic strategies with reduced adverse effects.
Purpose of the Study:
- To identify a compound that selectively targets and eliminates glioma cells.
- To elucidate the molecular mechanisms underlying the selective cytotoxicity of the identified compound.
Main Methods:
- Screening of compounds for selective induction of cell death in glioma cells versus astrocytes.
- Analysis of microRNA (miR-494) and protein (CDC20) expression levels in response to compound treatment.
Main Results:
- Compound "331" demonstrated selective induction of cell death in glioma cells, sparing astrocytes.
- Treatment with compound 331 led to increased miR-494 levels and decreased CDC20 levels specifically in glioma cells.
Conclusions:
- Compound 331 exhibits potential as a targeted therapeutic agent for malignant gliomas.
- The selective anti-glioma activity of compound 331 is mediated through the upregulation of miR-494 and downregulation of CDC20.
Related Concept Videos
MicroRNAs
MicroRNAs
Abnormal Proliferation
Induced Pluripotent Stem Cells
Somatic...

